Single-Domain Antibodies as Carriers for Selective Targeting of Oral Subunit Vaccines
Recorded event — October 20, 2020
During the past decades, particular interest has been focused on developing effective mucosal vaccines because of their efficiency inducing mucosal and systemic immune responses. However, because of several hurdles, only a handful of mucosal vaccines are commercially available. Orally administered mucosal vaccines pass through host defenses the same way microbial pathogens do; they are diluted in mucosal secretions, degraded by proteases, and subunit vaccines are often not very immunogenic. A promising approach to address low immunogenicity of subunit vaccines is to target the antigen selectively to the receptors in mucosal membranes as an antigen-antibody fusion. Aminopeptidase N (APN) has been identified as the receptor through which some enteric pathogens make their entry. And antibodies against this receptor are known for their internalization across the mucosal surface through this receptor. Here we report the first phase in engineering a novel antigen carrier by fusing a target antigen to an anti-APN antibody.